Polyvalent immunoglobulins – Part 2: use in Belgium

de Meester C, Bourgeois J, Devriese S, San Miguel L
Record ID 32018001033
English
Authors' objectives: The Belgian authorities requested the support of KCE to offer recommendations regarding the indications in which Ig are most effective (KCE report published in February 2020), as well as approximations to the required quantity of Ig needed to respond to patient needs in those indications. Five research questions were drafted and the analysis was conducted in 2 different phases/reports. In the first phase, captured in a report published in February 2020, indications for Ig use were studied, based on a review of the available literature and an international comparison, while this second phase, offers a more detailed data analysis of the Belgian situation/usage of Ig in order to offer an approximation to future needs. Usage and trends are therefore, the main focus of this report. Project research questions: - What are the most frequent indications forwhich Ig is used in Belgium? - What is the use/consumption of Ig in Belgium, and what are the possible trends for the coming years?
Authors' results and conclusions: Results can be consulted in the KCE Report 336. Conclusions are available in Dutch (KCE Report 336A) or French (KCE Report 336B) only.
Authors' recommendations: Recommendations have been provided to the following stakeholders: Health Minister, Health ministry, National health insurance, Medicines agency, Public health institute, Superior Health Council, Scientific community, Clinicians, Hospitals, Pharmacists in hospitals, Mutualities, Medicine Industry and Wholesalers Recommendations are available in Dutch (KCE Report 336A) or French (KCE Report 336B) only.
Details
Project Status: Completed
Year Published: 2020
URL for published report: https://doi.org/10.57598/R336C
URL for additional information: https://kce.fgov.be/en/polyvalent-immunoglobulins-%E2%80%93-part-2-use-in-belgium
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Belgium
DOI: 10.57598/R336C
MeSH Terms
  • Immunoglobulins, Intravenous
  • Infusions, Subcutaneous
  • Immunoglobulin G
  • Immunoglobulins
  • Immunologic Deficiency Syndromes
  • Immune System Diseases
  • Autoimmune Diseases
Keywords
  • Medicine/therapeutic use
  • Intravenous Immunoglobulins
  • Subcutaneous Infusions
Contact
Organisation Name: Belgian Health Care Knowledge Centre
Contact Address: Administrative Centre Botanique, Doorbuilding (10th floor), Boulevard du Jardin Botanique 55, B-1000 Brussels, Belgium tel: +32 2 287 33 88 fax: +32 2 287 33 85
Contact Name: info@kce.fgov.be
Contact Email: info@kce.fgov.be
Copyright: Belgian Health Care Knowledge Centre (KCE), CC-BY-NC-ND
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.